Screening & Diagnostics - Cancer & Chronic Disease
Astra Zeneca - looking to Improve Product Competitiveness by giving our customers the ability to access diagnostic tools that could be used at home by the patient, by a clinician or used in a lab.
AstraZeneca has historically serviced patients at the treatment stage of their disease lifecycle. In recent years, their commercial strategy has changed and are now looking to partner with companies across the care continuum.
As part of this, AstraZeneca is looking to partner with service providers who operate in the screening and early diagnosis in chronic kidney diseases, lung cancer, prostate cancer, breast cancer, ovarian cancer, haematology, heart failure, severe asthma and COPD.
These diagnostic tools could be for at home use by the patient, use by the clinician or use in the lab.
AstraZeneca are focusing on 3 solution areas:
- Aus/NZ based technology or solutions in development stage
- Aus/NZ based technology or solutions already in the market or ready for regulatory approval in the next 12-18 month.
- Global technology or solutions with approval in their local markets who could gain regulatory TGA approval.